Adalvo Acquires Romiplostim Biosimilar Program
The firm enters the biologics market, while Enzene pivots its business model to focus on contract manufacturing services.
Updated on Oct. 27, 2026 in Healthcare
Live Poll
Does the shift toward contract manufacturing for biosimilar drugs lead to lower prices for patients?
Adalvo has acquired a romiplostim biosimilar program from Enzene, marking the firm's entry into the biologics market. The partnership maintains Enzene as the contract manufacturer, supporting global regulatory filings for the treatment as they transition to a pure-play manufacturing model.
Why it matters
This deal allows Adalvo to expand into the high-value biologics space while enabling Enzene to shed its commercial program to focus exclusively on contract manufacturing for pharmaceutical partners. The move targets a segment defined by the reference product Nplate, which recorded $1.5 billion in global sales during 2025.
The reference biologic Nplate generated $1.5 billion in global sales in 2025. Adalvo now aims to leverage its network across 140 countries and 170 existing pharmaceutical partnerships to compete against the established originator product.
The players
Adalvo
A pharmaceutical company based in Switzerland that operates with over 170 partners across 140 countries.
Enzene
An Indian contract development and manufacturing organization that produces biologics at its Pune facilities.
Amgen
The biotechnology firm that received initial FDA approval for the originator product Nplate.
The details
Under the terms of the agreement, Enzene will utilize its good manufacturing practice-approved facilities in Pune, India, to produce the romiplostim biosimilar. Adalvo assumes control of the commercial program, while Enzene provides the technical support necessary for navigating the regulatory pathways of the FDA and the European Medicines Agency. This arrangement allows Adalvo to tap into Enzene's existing manufacturing infrastructure to scale production for international markets.
Timeline
2008: FDA first approved Nplate.
August 2021: Enzene received romiplostim marketing authorization in India.
2025: Nplate global sales reached $1.5 billion.
October 27, 2026: Adalvo announced the acquisition of the biosimilar program.
Market Landscape
This acquisition follows the long-standing competitive path set by the FDA's 2008 approval of Nplate. The move reflects a broader trend of mid-market pharmaceutical firms entering the biologics sector by leveraging established contract manufacturing partners.
Operators in the pharmaceutical space should monitor the regulatory filing timelines for this biosimilar as a signal for potential competitive pricing pressure on biologic portfolios. Firms should reevaluate their contract manufacturing dependencies in light of Enzene's shift toward a service-only business model.
The takeaway
The acquisition signals a shift toward specialized contract-manufacturing partnerships in the biologics sector. Businesses should track regulatory filings for biosimilar candidates to project when entry-level competition might disrupt high-cost, legacy biologic market shares.
Further reading
For broader trends in drug development and industry consolidation, explore the Healthcare section.
Source note: This article includes information reported by BioPharm International.
Live Poll
Does the shift toward contract manufacturing for biosimilar drugs lead to lower prices for patients?
